Mirum Pharmaceuticals (NASDAQ: MIRM) holder to sell 6,831 shares after RSU vest

Rhea-AI Filing Summary

Mirum Pharmaceuticals stockholder plans to sell recently vested shares. A person named Christopher Peetz filed a notice to sell 6,831 shares of Mirum Pharmaceuticals common stock through Morgan Stanley Smith Barney LLC on or about 01/26/2026 on NASDAQ, with an aggregate market value of 662,060.52.

These shares were acquired on 01/23/2026 as restricted stock units vesting under a registered plan, as compensation for services rendered to the issuer. The notice also reports that during the past three months, the same seller disposed of 7,098 shares of common stock for gross proceeds of 662,422.46.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC 1 New York Plaza, 8th Floor New York NY 10004	6831	662060.52	51393574	01/26/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/23/2026	Restricted Stock Units vesting under registered plan	Issuer			6831	01/23/2026	Compensation for services rendered to Issuer

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Christopher Peetz c/o Mirum Pharmaceuticals, Inc. 989 E Hillsdale Blvd., Suite 300 Foster City CA 94404	Common Stock	01/22/2026	7098	662422.46

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for MIRM disclose?

The Form 144 discloses that stockholder Christopher Peetz plans to sell 6,831 shares of Mirum Pharmaceuticals common stock. The planned sale will be executed through Morgan Stanley Smith Barney LLC on NASDAQ, following vesting of restricted stock units under a registered compensation plan.

How many Mirum Pharmaceuticals (MIRM) shares are planned to be sold?

The filing indicates an intent to sell 6,831 shares of Mirum Pharmaceuticals common stock. These shares were recently acquired through vesting of restricted stock units and have an aggregate market value of 662,060.52 based on the figures provided in the document.

How were the MIRM shares in the Form 144 acquired?

The shares to be sold were acquired on 01/23/2026 as restricted stock units vesting under a registered plan. The filing states they were received as compensation for services rendered to Mirum Pharmaceuticals, rather than being purchased for cash in the open market.

What prior Mirum Pharmaceuticals stock sales by this seller are reported?

The document reports that over the past three months, Christopher Peetz sold 7,098 shares of Mirum Pharmaceuticals common stock. Those earlier sales generated gross proceeds of 662,422.46, and are listed to provide context for recent and planned disposition activity.

On which exchange will the MIRM shares in this Form 144 be sold?

The filing specifies that the 6,831 Mirum Pharmaceuticals common shares are expected to be sold on NASDAQ. Morgan Stanley Smith Barney LLC is listed as the broker handling the transaction, with an approximate sale date of 01/26/2026 provided in the document.

How many Mirum Pharmaceuticals (MIRM) shares are outstanding in this filing?

The Form 144 notes that 51,393,574 shares of Mirum Pharmaceuticals common stock were outstanding. This figure provides context for the planned 6,831-share sale reported for Christopher Peetz, showing the relative size of the proposed transaction versus total shares.